Kairos Pharma, Ltd. (NYSE American: KAPA) announced it will be presenting data at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting. The conference is scheduled to take place from May 30 to June 3, 2025, in Chicago, Illinois.
The company will present a poster on June 2, titled 'Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity.' This presentation highlights Kairos Pharma's ongoing research into its platform assets.
CEO John Yu, M.D., stated that the company looks forward to sharing data regarding its platform assets at one of the most prestigious oncology meetings globally. This engagement provides an opportunity to discuss findings with the medical and scientific communities, underscoring the potential of KROS 101 to optimize cancer treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.